Loading...
XETR
BAYN
Market cap38bUSD
Dec 04, Last price  
33.56EUR
1D
-2.01%
1Q
19.18%
Jan 2017
-65.48%
Name

Bayer AG

Chart & Performance

D1W1MN
XETR:BAYN chart
P/E
P/S
0.71
EPS
Div Yield, %
0.33%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
1.37%
Revenues
46.61b
-2.16%
27,362,398,48028,955,881,04032,385,000,00032,918,000,00031,168,000,00035,088,000,00036,528,000,00039,760,000,00040,157,000,00042,239,000,00046,324,000,00046,769,000,00035,015,000,00039,586,000,00043,545,000,00041,400,000,00044,081,000,00050,739,000,00047,637,000,00046,606,000,000
Net income
-2.55b
L-13.23%
1,594,057,2801,694,952,5304,711,000,0001,719,000,0001,359,000,0001,301,000,0002,470,000,0002,446,000,0003,189,000,0003,426,000,0004,110,000,0004,531,000,0007,336,000,0001,695,000,0002,430,000,000-15,561,000,0001,000,000,0004,150,000,000-2,941,000,000-2,552,000,000
CFO
7.37b
+43.99%
3,499,664,9504,202,906,4304,283,000,0003,608,000,0005,375,000,0005,773,000,0005,060,000,0004,532,000,0005,171,000,0005,810,000,0006,890,000,0009,089,000,0008,134,000,0007,917,000,0008,207,000,0004,903,000,0005,089,000,0007,093,000,0005,117,000,0007,368,000,000
Dividend
Apr 28, 20250 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
IPO date
Nov 28, 1997
Employees
102,048
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT